Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to Lumos Pharma's Second Quarter 2024 Financial Results and Clinical Programs Update Call. Currently, all participants are in a listen-only mode.
Lumos Pharma Inc. (LUMO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 213,814 | $827,460 | -1% | 0% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 120,651 | $466,919 | 0% | |
| 3. | Lion Point Didric Cederholm | 39,589 | $153,209 | -57% | 0.34% |
| 4. | ADAR1 Capital Management Daniel Schneeberger | 10,000 | $38,700 | 0% | |
| 5. | Millennium Management Israel Englander | 0 | $0 | -100% | 0% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 417,051 | $1,326,222 | 0% | |
| 2. | 406,611 | $1,293,023 | 0% | |
| 3. | 326,552 | $1,038,435 | 0% | |
| 4. | 244,082 | $776,181 | 0% | |
| 5. | 125,282 | $394,202 | 0.2% |
News See All
Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2024 Earnings Call Transcript
Operator: Greetings, and welcome to Lumos Pharma First Quarter 2024 Financial Results and Clinical Programs Update Call. At this time, all participants are in a listen-only mode.
Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to Lumos Pharma’s 2023 Fourth Quarter and Year End Conference Call. Currently all participants are on a listen-only mode.
Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Lumos Pharma's Q2 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Lumos Pharma's Q1 2023 Financial Results Conference Call. [Operator Instructions]. As a reminder, this conference call is being recorded.
Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to Lumos Pharma's 2022 Financial Results Conference Call. We'll now turn the call over to Lisa Miller, Senior Director of Investor Relations.
Is LUMO Stock A Buy?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second ...
Is Lumos Pharma (LUMO) A Good Stock To Buy Now?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
Is Lumos Pharma, Inc. (LUMO) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Billionaire Hedge Funds
